Category Archives: FDA Policy

Promotion of Investigational Compound – Historical Overview

Communications regarding medicines in development – often referred to as “investigational compounds” can be particularly challenging. On the one hand, there are data milestones and advancements for the product through the regulatory cycle about which there is great interest. On … Continue reading

Posted in FDA Policy, Regulatory Communications, Warning Letters | Comments Off

FDA Guidance Output Plans for 2016

While there has been focus on what FDA accomplished in 2015 – and there will continue to be some of that – it is also a great time to look ahead. What can we anticipate for 2016? This month several … Continue reading

Posted in FDA Policy | Comments Off

FDA 2015 Report on New Drug Approvals – A Banner Year

Greetings from the big blizzard of 2016. With life in the slow lane for a bit, it was a good time to catch up on reading. One of those was a recently issued FDA report on the novel new drugs … Continue reading

Posted in Approval Announcements, FDA Policy | Comments Off

FDA Press Release 2015 – What They Said

Last year and the year before, Eye on FDA provided an overview of press releases from the agency for the year that had just passed. The information comes from a database of press releases that I started back in 2013 … Continue reading

Posted in FDA Image, FDA Policy | Comments Off

The Growing World of Do It Yourself Health

Sparked by an inquiry regarding a speaking gig around the future of do-it-yourself (DIY) medicine got me to thinking about how much the concept has changed over the years, and most certainly at an accelerating pace. Back in 2011, I … Continue reading

Posted in Current Affairs, FDA Policy | Comments Off